WO1998033474A1 - Utilisation d'huile en tant que vehicule a travers la membrane de medicaments et de proteines - Google Patents

Utilisation d'huile en tant que vehicule a travers la membrane de medicaments et de proteines Download PDF

Info

Publication number
WO1998033474A1
WO1998033474A1 PCT/US1998/001587 US9801587W WO9833474A1 WO 1998033474 A1 WO1998033474 A1 WO 1998033474A1 US 9801587 W US9801587 W US 9801587W WO 9833474 A1 WO9833474 A1 WO 9833474A1
Authority
WO
WIPO (PCT)
Prior art keywords
oil
emu
composition
active agent
rhea
Prior art date
Application number
PCT/US1998/001587
Other languages
English (en)
Inventor
Kenneth Hoyt
Paul Lemley
Original Assignee
Kenneth Hoyt
Paul Lemley
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kenneth Hoyt, Paul Lemley filed Critical Kenneth Hoyt
Priority to AU60461/98A priority Critical patent/AU6046198A/en
Publication of WO1998033474A1 publication Critical patent/WO1998033474A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59

Definitions

  • This invention relates to use of oil from birds, particularly from the emu and rhea birds.
  • Compositions containing the oil of the birds as carriers for therapeutic or immunogenic 5 . agents are disclosed.
  • U.S. Patent 5,472,713 discloses use of emu oil for lowering cholesterol, triglycer- 0 ides and low density lipoproteins, for increasing high density lipoproteins and for other medicinal purposes.
  • the oil is administered parenterally, orally, rectally or topically to the mucosa. In the later instance, application is to the mucosa.
  • the emu oil does not act as a carrier for other active agents.
  • U.S. Patent 5,431,924 teaches use of emu oil as an anti- inflammatory agent.
  • That patent teaches and claims a method of preparing a yellow extract of emu oil as an anti-inflammatory and relies on other agents to transport of the oil across the dermis or mucous membranes.
  • the emu oil extracts for anti- 0 inflammatory purposes are prepared using organic solvents.
  • it is necessary to prepare compositions for anti-inflammatory use by adding to the yellow emu oil obtained by the methods of '924 certain diluents to potentiate the anti- inflammatory activity of the emu oil and to act as transport 5 agents.
  • emu oil in and of itself, acts as a transport agent for other active agents such as pharmaceuticals and vaccines. Summary of the Invention:
  • This invention provides a method for transdermal transpor- 0 tation of proteins, peptides and other therapeutic agents.
  • the method may also be used to facilitate transport across other animal membranes.
  • a preferred method of preparing the oil for use in accord with the objectives of the invention comprises the steps of 1) breaking up the tallow from the sebaceous gland; 2) rendering the tallow prepared in step 1 in the presence of steam at a temperature of about 140 °F; 3) drawing off the oil rendered in step 2; 4) straining the product of step 3 to remove foreign 5 . and extraneous protein; and 5) removing the remaining water from the oil.
  • compositions of the invention are prepared by adding active agents such as peptides, proteins or other active therapeutic or disease-preventing agents to the emu oil. These 0 compositions are then applied to the skin or other epithelial tissue, including the mucosa. Detailed description of the invention:
  • the method described herein is particularly useful for transport of peptides and proteins.
  • By means of the invention it is possible to administer vaccines without use of 0 sterile equipment or solutions. This benefit will be especially appreciated by those responsible for administering antigens in countries where refrigeration and sterile materials and equipment are not readily available.
  • the methods of the invention make it possible to vaccinate populations without 5 needles and to administer prophylactic or therapeutic proteins, peptides and other active agents without breaking the skin.
  • the use of the oil also facilitates transport across cell membranes .
  • the methods of the invention are of special value for use 0 in administration of lipophilic compounds such as steroids which may be detoxified in the liver.
  • lipophilic compounds such as steroids which may be detoxified in the liver.
  • testosterone can be less toxic when administered in a manner that bypasses the liver.
  • Other active agents such as analgesics, antihistamines, anesthetics, lipophilic antimicrobials, anti- 5 inflammatory agents, anti-cancer agents, oil-soluble vitamins, etc. may be administered by the methods of the invention.
  • Materials and Methods Preparation of the oil:
  • a preparation of oil from the rhea bird was made. Adipose tissue from the sebaceous gland from the bird was ground in a meat grinder to break down the tallow and allow larger surface 5 . areas. The ground tallow was then rendered in a steam kettle at a temperature of 140 °F. The oil was drawn off as it was rendered from the adipose tissue.
  • the oil was strained in a 10 micron filter using a vacuum pump. 0 (The oil was maintained at 140 °F during this process.) After the oil had been strained and all foreign and extraneous protein removed, the oil was again heated to 140°F. The oil was maintained at that temperature until all water had evaporated from the oil. (Approximately six hours was 5 required.) The oil so obtained was strained again by the method described above. The oil was then placed in glass containers and vacuum sealed using a pressure cooker at 15 pounds pressure for 20 minutes.
  • Emu oil may be prepared in the same manner for purposes of this invention. 5 It is known that rhea and emu oils contain a number of different fatty acid chains.
  • U.S. Patent 5,431,924 to Ghosh, et al. teaches emu oil made by fractionating the oil with hexane using a florisil column, eluting the column with hexane, dichloro ethane and methanol and separating a biologically 0 active yellow colored component from the oil to obtain a yellow residue. It is obvious that the method of preparing emu oil as taught herein is far simpler than that of Ghosh, et al. Use of oil as a carrier:
  • antigens were mixed with 5 the oil obtained by the methods described above. The oil was then applied to a clean-shaven patch of skin of mice. During testing, 30 to 50 ⁇ l of oil was used for each administration. However, amounts of oil used for administration in accord with the teaching of the invention may vary depending on the agent to be administered. It is expected that the amount used will usually be in amount of 1 to 1000 ⁇ l per dose. The method was tested using agents of varying molecular weights ( ⁇ 2000 daltons to >60,000 daltons) and using both naturally-occurring and recombinant proteins.
  • antigenic proteins were administered and the level of antibody production evaluated.
  • the test animals were pre-bled and tested to assure that the animal had no antibodies against the immunogen to be administered in the compositions.
  • An anti-allergic composition is prepared using 1 ml of oil prepared by the method described above having added thereto 5 mg dexamethasone. The resulting composition is administered by application to the skin.
  • a nine amino acid sequence known as delta sleep inducing peptide (DSIP) of the structure Trp-Ala-Gly-Gly-Asp-Ala-Ser- Gly-Glu is formulated by adding D50 ⁇ l DSIP to 100 ⁇ l emu oil prepared in accord with the teachings above.
  • Such peptides include splenopentin (SP-5) having the structure Arg-Lys-Glu-Val-Tyr . This peptide is effective for inducing T-cell differentiation and for modulation of neuromus- cular transmission. (Proc. Natl. Acad. Sci.
  • VIP vasoactive intestinal peptide
  • biotinyl-VIP from human, porcin, chick, rat, or others, having the sequence His-Ser-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg- Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn-NH 2 for prevention of cell death caused by human immunodeficiency virus (Nature 335: 639-642 (1984)) and for pharmacological treatment of tissues involving neuromuscular transmission (Arch, int. Phar acodvn 305, 14-24 (1990)).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un procédé servant à véhiculer par voie transdermique des protéines, des peptides ou d'autres agents thérapeutiques et utilisant l'huile obtenue depuis les glandes sébacées d'oiseaux, tels que l'émeu. On peut également mettre ce procédé en application afin de faciliter le transport à travers d'autres membranes animales.
PCT/US1998/001587 1997-01-31 1998-01-30 Utilisation d'huile en tant que vehicule a travers la membrane de medicaments et de proteines WO1998033474A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU60461/98A AU6046198A (en) 1997-01-31 1998-01-30 Use of oil from emu or rhea birds as trans-membrane carriers for delivery of drugs, peptides and vaccines

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3676797P 1997-01-31 1997-01-31
US60/036,767 1997-01-31

Publications (1)

Publication Number Publication Date
WO1998033474A1 true WO1998033474A1 (fr) 1998-08-06

Family

ID=21890528

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/001587 WO1998033474A1 (fr) 1997-01-31 1998-01-30 Utilisation d'huile en tant que vehicule a travers la membrane de medicaments et de proteines

Country Status (2)

Country Link
AU (1) AU6046198A (fr)
WO (1) WO1998033474A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6531126B2 (en) 1999-08-26 2003-03-11 Ganeden Biotech, Inc. Use of emu oil and its various fractions as a carrier for antifungal, antibacterial, and antiviral medications and preparations
US6759056B2 (en) 1998-07-08 2004-07-06 Oryxe Mixture for transdermal delivery of low and high molecular weight compounds
US6951658B1 (en) 2003-07-08 2005-10-04 Pearson Research & Development Limited Emu-based compositions for mental well-being and method of use
US7220427B2 (en) 1998-07-08 2007-05-22 Oryxe Mixture for transdermal delivery of low and high molecular weight compounds
US20120156258A1 (en) * 2005-08-01 2012-06-21 Hisamitsu Pharmaceutical Co., Inc. Adjuvant or pharmaceutical preparation for transdermal or transmucosal administration
WO2013158318A1 (fr) * 2012-04-16 2013-10-24 Zemtsov Enterprises, Llc Formulations et procédés pour le traitement de l'acné et d'affections cutanées inflammatoires
US9993549B2 (en) 2013-10-31 2018-06-12 Hisamitsu Pharmaceutical Co., Inc. Adjuvant composition, adjuvant preparation containing same, and kit
US11260018B2 (en) 2015-09-17 2022-03-01 Jrx Biotechnology, Inc. Approaches for improving skin hydration and moisturization

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992008470A1 (fr) * 1990-11-14 1992-05-29 Emu Products Western Australia Pty. Ltd. Composition anti-inflammatoire tiree de l'huile d'emeu
US5472713A (en) * 1994-11-23 1995-12-05 Elf Resources, Inc. Therapeutic uses of emu oil
WO1996034596A2 (fr) * 1995-05-03 1996-11-07 Holick, Michael, F. Utilisation d'huile d'emeu pour stimuler la croissance de la peau et des cheveux
US5725858A (en) * 1994-02-28 1998-03-10 Agritech Technologies, Ltd. Methods of enhancing production performance of birds comprising administration of heterologous protein comprising avian alpha-subunit inhibin protein

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992008470A1 (fr) * 1990-11-14 1992-05-29 Emu Products Western Australia Pty. Ltd. Composition anti-inflammatoire tiree de l'huile d'emeu
US5725858A (en) * 1994-02-28 1998-03-10 Agritech Technologies, Ltd. Methods of enhancing production performance of birds comprising administration of heterologous protein comprising avian alpha-subunit inhibin protein
US5472713A (en) * 1994-11-23 1995-12-05 Elf Resources, Inc. Therapeutic uses of emu oil
WO1996034596A2 (fr) * 1995-05-03 1996-11-07 Holick, Michael, F. Utilisation d'huile d'emeu pour stimuler la croissance de la peau et des cheveux

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6759056B2 (en) 1998-07-08 2004-07-06 Oryxe Mixture for transdermal delivery of low and high molecular weight compounds
US6946144B1 (en) 1998-07-08 2005-09-20 Oryxe Transdermal delivery system
US7201919B2 (en) 1998-07-08 2007-04-10 Jordan Frederick L Mixture for transdermal delivery of low and high molecular weight compounds
US7220427B2 (en) 1998-07-08 2007-05-22 Oryxe Mixture for transdermal delivery of low and high molecular weight compounds
US7300666B2 (en) 1998-07-08 2007-11-27 Jrx Biotechnology, Inc. Mixture for transdermal delivery of low and high molecular weight compounds
US7316820B2 (en) 1998-07-08 2008-01-08 Jrx Biotechnology, Inc. Mixture for transdermal delivery of low and high molecular weight compounds
US7371407B2 (en) 1999-08-26 2008-05-13 Ganeden Biotech, Inc. Use of Emu Oil and its various fractions as a carrier for antifungal, antibacterial, and antiviral medications and preparations
US6733751B2 (en) 1999-08-26 2004-05-11 Ganeden Biotech, Inc. Use of Emu Oil and its various fractions as a carrier for antifungal, antibacterial, and antiviral medications & preparations
US6531126B2 (en) 1999-08-26 2003-03-11 Ganeden Biotech, Inc. Use of emu oil and its various fractions as a carrier for antifungal, antibacterial, and antiviral medications and preparations
US7048950B2 (en) 1999-08-26 2006-05-23 Ganeden Biotech, Inc. Use of Emu Oil and its various fractions as a carrier for antifungal, antibacterial, and antiviral medications and preparations
US6951658B1 (en) 2003-07-08 2005-10-04 Pearson Research & Development Limited Emu-based compositions for mental well-being and method of use
US20120156258A1 (en) * 2005-08-01 2012-06-21 Hisamitsu Pharmaceutical Co., Inc. Adjuvant or pharmaceutical preparation for transdermal or transmucosal administration
US8858962B2 (en) * 2005-08-01 2014-10-14 Hisamitsu Pharmaceutical Co., Inc. Adjuvant or pharmaceutical preparation for transdermal or transmucosal administration
WO2013158318A1 (fr) * 2012-04-16 2013-10-24 Zemtsov Enterprises, Llc Formulations et procédés pour le traitement de l'acné et d'affections cutanées inflammatoires
WO2013158317A1 (fr) * 2012-04-16 2013-10-24 Zemtsov Enterprises, Llc Formulations et procédés pour le traitement de maladies inflammatoires de la peau
US11224618B2 (en) 2012-04-16 2022-01-18 Zemtsov Enterprises, Llc Formulations and methods for treatment of acne and inflammatory skin conditions
US11224619B2 (en) 2012-04-16 2022-01-18 Zemtsov Enterprises, Llc Formulations and methods for treatment of inflammatory skin diseases
US9993549B2 (en) 2013-10-31 2018-06-12 Hisamitsu Pharmaceutical Co., Inc. Adjuvant composition, adjuvant preparation containing same, and kit
US11260018B2 (en) 2015-09-17 2022-03-01 Jrx Biotechnology, Inc. Approaches for improving skin hydration and moisturization

Also Published As

Publication number Publication date
AU6046198A (en) 1998-08-25

Similar Documents

Publication Publication Date Title
EP1009430B1 (fr) Emulsion huile/eau de vaccins contre l'Hepatite B
US20230233658A1 (en) Formulation of a peptide vaccine
DE69534992T2 (de) Mutierendes enterotoxin als nichttoxisches orales adjuvans
AT408721B (de) Pharmazeutische zusammensetzung enthaltend ein antigen
JP5722782B2 (ja) ナノエマルジョン治療用組成物及びその使用方法
KR100342942B1 (ko) 카르두스 마리아누스 추출물 또는 이로부터 정제된 실리빈을함유하는 경구용 마이크로에멀젼 조성물
FR2598622A1 (fr) Adjuvants immunologiques pour vaccins polysaccharidiques
Lindblad Freund's adjuvants
CN113698472B (zh) 一种高纯度小分子鱼皮胶原蛋白肽的制备方法以及鱼皮胶原蛋白肽喷雾剂
WO1998033474A1 (fr) Utilisation d'huile en tant que vehicule a travers la membrane de medicaments et de proteines
KR20090019760A (ko) 양명아주 추출물을 함유하는 약학 조성물, 및 이의 제조방법 및 용도
DE69830900T2 (de) Immunologische toleranz-induzierende zusammensetzungen enthaltend antigen und mucosabindungskomponente
JP5752343B2 (ja) Ｓ／ｏ型経皮免疫剤
AU2002350380B2 (en) An organic extract of Geum Japonicum thumb variant and use thereof
Israf et al. Enhancement of ovalbumin-specific IgA responses via oral boosting with antigen co-administered with an aqueous Solanum torvum extract
JP2016026203A (ja) 人間、動物およびバイオテクノロジー産業において、ｒｎａウイルスと、それによって引き起こされる感染または疾患を、予防、除去、治療するための、ピクロリザ・クロア抽出物
EP1154792B1 (fr) Composition de vaccin contre la tuberculose contenant des monoglycerides d'acides gras comme adjuvant
WO2010013350A1 (fr) Agent d'immunisation transdermique de type s/o
Ben-David et al. Production of lactation by non-sedative phenothiazine derivatives.
WO1999007395A1 (fr) Compositions de polygala senega et leurs procedes d'utilisation
Kazmierczak et al. Biliary tract excretion of ofloxacin in man
JP2001520647A (ja) リュウマトイド関節炎の処置用軟骨オリゴマーマトリクスタンパク質の使用
JP2002145791A (ja) 抗炎症性組成物
EA042668B1 (ru) Композиция пептидной вакцины
KR0173365B1 (ko) C형 간염 바이러스의 펩타이드 항원을 함유하는 리포좀

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998533018

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase